GSK3B and myotonic dystrophy type 1: Since the TG-GSK3β pathway reduces the mutant DMPK mRNA in human DM1 cells and CUG-containing transcripts in HSALR muscle [18], the increased levels of active GSK3β in PBMCs in DM1 patients could be used as one of the potential biomarkers to monitor the effects of these therapeutics.